Samsung Biologics Adopts Solentim Solutions In R&D Center

Solentim’s instruments will be used in conjunction with Samsung Biologics’ proprietary cell line platform.

Contract Pharma Staff10.07.20

Solentim’s VIPS single cell seeding platform and Cell Metric CLD have been adopted into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development.
 
Samsung’s new R&D facility in San Francisco will offer rapid, high-quality development services, including cell line development, to its global customers. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice, announced last month.
 
“We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations,” said Dr. Mark Truesdale, CEO of Solentim.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *